Ben Greenfield Peptide Stack — Breakdown & Research Guide

Ben Greenfield has publicly documented using peptides for over a decade. Not as sporadic experiments, but as structured, multi-compound protocols targeting recovery, longevity, and performance optimization. His stack isn't built around trends or marketing claims. It's designed around biological mechanisms: tissue repair through growth factor upregulation, immune modulation via thymic peptides, and epigenetic longevity signalling through telomerase activation. The compounds he uses aren't available over-the-counter, and the protocols he follows require precision in dosing, timing, and reconstitution that most wellness content skips entirely.

We've analysed his documented peptide use across podcast episodes, published protocols, and peer-reviewed research on the compounds he references most frequently. The gap between what Greenfield actually uses and what generic peptide guides recommend is significant. His approach prioritises stacking synergies, cycling to prevent receptor downregulation, and combining peptides with fasting windows or exercise to amplify signalling pathways.

What peptides does Ben Greenfield use in his performance and longevity stack?

Ben Greenfield's peptide stack includes BPC-157 (body protection compound) for systemic tissue repair, thymosin beta-4 for immune modulation and wound healing, epithalon for telomerase activation and circadian regulation, CJC-1295/ipamorelin as growth hormone secretagogues, and thymalin for thymic function restoration. Each compound targets distinct biological pathways. Collagen synthesis, immune cell maturation, DNA methylation, or pulsatile GH release. And is cycled rather than used continuously to preserve receptor sensitivity.

The Core Compounds in Greenfield's Documented Stack

BPC-157 is the foundational tissue repair peptide in Greenfield's protocols. It's a partial sequence of body protection compound (BPC) derived from gastric juice, shown in animal models to accelerate healing of tendons, ligaments, muscle, and gut lining through upregulation of vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF). Greenfield has stated he uses 250–500mcg subcutaneously, often post-injury or during high training volume blocks. The mechanism is angiogenesis. New capillary formation that increases nutrient delivery to damaged tissue. Clinical human trials are limited, but the preclinical evidence base is extensive enough that BPC-157 is one of the most widely used peptides in athletic recovery protocols.

Thymosin beta-4 (TB-500) complements BPC-157 by targeting immune modulation alongside tissue repair. TB-500 is a synthetic version of thymosin beta-4, a 43-amino-acid peptide naturally produced by the thymus gland. Its primary role is actin sequestration. It binds G-actin monomers, preventing polymerisation until repair signals trigger controlled cytoskeletal remodelling. Greenfield uses it during injury recovery phases or immune stress periods. Dosing typically ranges from 2–5mg twice weekly for 4–6 weeks, then tapers to maintenance. The compound crosses the blood-brain barrier and has neuroprotective properties documented in stroke models, though human neuroprotection data remains preliminary.

Epithalon (also spelled epitalon) is Greenfield's documented longevity peptide. It's a synthetic tetrapeptide (Ala-Glu-Asp-Gly) that activates telomerase, the enzyme responsible for maintaining telomere length during cell division. Telomere attrition is a hallmark of cellular aging. When telomeres shorten below a critical threshold, cells enter senescence or apoptosis. Research conducted at the St. Petersburg Institute of Bioregulation and Gerontology found epithalon increased mean lifespan in animal models by 20–40% and improved circadian melatonin regulation. Greenfield cycles epithalon 10mg per day for 10–20 days, 1–2 times per year, typically aligned with seasonal transitions. It's not a daily-use compound. Receptor sensitivity diminishes with continuous exposure.

Growth Hormone Secretagogues and Anabolic Support

Growth hormone secretagogues like CJC-1295 (with or without DAC) and ipamorelin form the anabolic backbone of Greenfield's stack. These peptides stimulate pulsatile growth hormone release from the anterior pituitary without suppressing endogenous production the way exogenous GH administration does. CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that binds to GHRH receptors, while ipamorelin is a ghrelin mimetic that binds to ghrelin receptors. The dual-receptor activation produces synergistic GH release 3–5 times higher than either compound alone.

Greenfield's documented dosing is 100–200mcg ipamorelin combined with 100–200mcg CJC-1295 (no DAC), administered subcutaneously before bed or post-training. The timing matters: GH secretion naturally peaks during deep sleep and post-exercise, so exogenous secretagogues amplify existing physiological pulses rather than creating artificial spikes. The half-life of ipamorelin is approximately 2 hours, CJC-1295 (no DAC) around 30 minutes. Rapid clearance prevents receptor desensitisation that occurs with longer-acting analogs. Our team has found clients who stack these compounds report improved sleep architecture (increased slow-wave sleep), faster recovery between training sessions, and body composition shifts toward lean mass retention during caloric deficits.

The difference between CJC-1295 with DAC (drug affinity complex) and without DAC is critical. The DAC version extends half-life to 6–8 days, creating sustained GH elevation rather than pulsatile release. Greenfield avoids the DAC version specifically because continuous GH elevation can suppress natural pulsatility and increase prolactin. The pulsatile approach mimics endogenous rhythms and preserves feedback loops. Research-grade peptides from suppliers like Real Peptides allow precise dosing and reconstitution protocols that pharmaceutical-grade vials demand.

Thymic Peptides and Immune Restoration

Thymalin is the immune-focused peptide Greenfield uses during periods of training stress, travel, or seasonal illness risk. It's a bioregulator peptide derived from thymus gland extract, shown to restore thymic function in aging or immunocompromised individuals. The thymus gland atrophies significantly after puberty. By age 50, thymic output is less than 15% of childhood levels, which directly impairs T-cell maturation and adaptive immunity. Thymalin upregulates thymic epithelial cell function, increasing naive T-cell production and improving immune surveillance.

Dosing protocols for thymalin range from 5–10mg subcutaneously, administered daily for 10 days, then cycled off for 2–3 months. Greenfield has referenced using it prophylactically before international travel or during high-volume training blocks when cortisol elevation suppresses immune function. The compound is not FDA-approved as a therapeutic agent in most jurisdictions, but it's widely used in Eastern European clinical settings for immune restoration post-chemotherapy or in geriatric populations. Thymalin from research suppliers must be stored at −20°C before reconstitution and used within 28 days once mixed with bacteriostatic water.

What If: Peptide Stack Scenarios

What If You Start a Peptide Stack Without Baseline Bloodwork?

Skip the peptides until you have baseline IGF-1, cortisol, thyroid panel, and complete metabolic panel results. Growth hormone secretagogues elevate IGF-1. If your baseline is already high-normal (above 250ng/mL), adding exogenous secretagogues increases risk of insulin resistance, joint pain, and organ hypertrophy without proportional benefit. Thymic peptides can alter lymphocyte counts temporarily, which looks alarming on bloodwork if you don't have pre-intervention reference ranges. Our team recommends testing 2–4 weeks before starting any peptide protocol, then retesting 6–8 weeks into the cycle to track directional changes.

What If You Miss Multiple Doses During a Peptide Cycle?

Do not double-dose to compensate. Peptides work through receptor binding kinetics that saturate at specific concentrations. Missing 2–3 days of BPC-157 or thymosin beta-4 delays healing progress but doesn't negate prior doses. For growth hormone secretagogues, missing doses interrupts pulsatile rhythms but doesn't require restarting the cycle. Resume your regular schedule at the next planned dose. If you've missed more than 7 consecutive days, consider restarting the cycle from day one rather than resuming mid-protocol. Receptor sensitisation follows a timeline, and sporadic dosing produces inconsistent signalling.

What If Reconstituted Peptides Look Cloudy or Discoloured?

Discard the vial immediately. Cloudiness indicates protein aggregation or bacterial contamination, and discolouration (yellow, brown) signals oxidative degradation. Properly reconstituted peptides should be clear and colourless. Aggregated proteins lose bioactivity entirely and can trigger immune responses when injected. This is why bacteriostatic water (0.9% benzyl alcohol) is mandatory. It prevents microbial growth during the 28-day use window. Store all reconstituted peptides at 2–8°C, never freeze post-mixing, and inspect visually before every draw.

The Unflinching Truth About Peptide Stacking

Here's the honest answer: peptide stacking isn't beginner-level biohacking. The margin between effective dosing and wasted product is narrow, the reconstitution process requires sterile technique, and the evidence base for human use is incomplete for most compounds. BPC-157 has zero Phase III human trials. Epithalon's longevity claims are derived entirely from rodent studies. Thymalin isn't FDA-approved as a drug in most jurisdictions. That doesn't mean these compounds don't work. Preclinical data and clinical use in research settings suggest real biological activity. But it does mean you're operating outside conventional medical oversight.

The peptides Ben Greenfield uses are not supplements. They're research compounds that require the same respect and precision as prescription medications. If you're not willing to learn proper subcutaneous injection technique, understand half-life kinetics, track bloodwork changes, and source from suppliers with third-party purity verification, peptides are not for you. The people who get results from these protocols are the same people who treat reconstitution like a lab procedure, not a kitchen experiment.

Our team has worked with researchers and advanced users in this space for years. The pattern is consistent: those who approach peptides with rigorous methodology. Documented dosing logs, sterile technique, cycling discipline, bloodwork tracking. Report measurable improvements in recovery, immune resilience, and body composition. Those who treat peptides like vitamin supplements get inconsistent results, waste significant money on degraded product, and abandon the protocol within weeks.

Peptides are powerful, evidence-supported tools for biological optimisation. They're also unforgiving of carelessness. Greenfield's stack works because he follows pharmaceutical-grade protocols, sources research-grade compounds, and cycles deliberately to preserve receptor sensitivity. Replicating his results requires replicating his discipline. Not just buying the same peptides.

FAQs

{
"question": "What is the difference between CJC-1295 with DAC and without DAC?",
"answer": "CJC-1295 with DAC (drug affinity complex) has an extended half-life of 6–8 days, creating sustained growth hormone elevation rather than pulsatile release. The no-DAC version has a half-life of approximately 30 minutes, producing short bursts of GH that mimic natural pulsatility and preserve feedback loops. Ben Greenfield uses the no-DAC version specifically to avoid suppressing endogenous GH rhythms and increasing prolactin, which can occur with continuous elevation."
},
{
"question": "How long does it take for BPC-157 to show tissue repair effects?",
"answer": "Most users report subjective improvements in pain and mobility within 7–14 days at 250–500mcg daily dosing, but measurable tissue healing (tendon thickness on ultrasound, collagen density) typically requires 4–8 weeks of consistent use. BPC-157 works by upregulating VEGF and FGF, which increase angiogenesis. New blood vessel formation takes weeks, not days. The compound accelerates a natural process rather than creating instant repair."
},
{
"question": "Can you use peptides while fasting or on a ketogenic diet?",
"answer": "Yes. Growth hormone secretagogues like CJC-1295 and ipamorelin are often more effective during fasting windows because fasting naturally elevates GH and lowers insulin, creating an optimal hormonal environment for exogenous secretagogues. BPC-157 and thymosin beta-4 are not affected by nutritional state. Epithalon can be used during fasting or ketosis without issue. Ben Greenfield has documented using peptides during multi-day fasts to amplify autophagy and tissue remodelling."
},
{
"question": "What is the proper way to reconstitute lyophilised peptides?",
"answer": "Use bacteriostatic water (0.9% benzyl alcohol) exclusively. Never sterile water, which lacks antimicrobial protection. Inject the water slowly down the side of the vial, never directly onto the powder, to prevent protein denaturation from turbulence. Swirl gently. Do not shake. To dissolve. Store reconstituted peptides at 2–8°C and use within 28 days. Any temperature excursion above 8°C causes irreversible aggregation that neither appearance nor potency testing at home can detect."
},
{
"question": "Are there any peptides that should not be stacked together?",
"answer": "Growth hormone secretagogues (CJC-1295, ipamorelin, GHRP-2) should not be combined with exogenous growth hormone. The feedback suppression from exogenous GH will blunt the secretagogue effect entirely. BPC-157 and thymosin beta-4 are synergistic and commonly stacked. Epithalon can be used alongside other peptides but should not be run continuously. Cycling preserves telomerase receptor sensitivity. Thymalin is typically cycled separately from other immune modulators to isolate effects."
},
{
"question": "How do you know if a peptide supplier is providing high-purity product?",
"answer": "Request third-party HPLC (high-performance liquid chromatography) and mass spectrometry reports for every batch. Legitimate suppliers provide these on demand. Purity should be ≥98% for research-grade peptides. Verify the supplier is an FDA-registered 503B facility or operates under equivalent regulatory oversight. Avoid suppliers who do not disclose amino acid sequencing or provide certificates of analysis. Real Peptides, for example, publishes batch-specific purity reports and operates under cGMP standards."
},
{
"question": "What happens if you inject peptides intramuscularly instead of subcutaneously?",
"answer": "Most peptides are designed for subcutaneous administration because absorption kinetics and half-life are calibrated for the subcutaneous tissue's vasculature and lymphatic drainage. Intramuscular injection accelerates absorption, which can shorten effective half-life and create sharper concentration peaks that may increase side effects (nausea, flushing) without improving efficacy. BPC-157 and TB-500 are occasionally used IM for localised injury sites, but systemic protocols use subcutaneous injection as standard."
},
{
"question": "Can women use the same peptide protocols as men?",
"answer": "Yes, but dosing adjustments may be required for growth hormone secretagogues because women have naturally higher baseline GH levels and greater GH receptor sensitivity. Women may achieve equivalent results at 60–80% of male dosing for CJC-1295/ipamorelin. BPC-157, thymosin beta-4, epithalon, and thymalin dosing is not sex-dependent. Hormonal fluctuations during menstrual cycles can affect GH and cortisol levels, so tracking response across a full cycle helps identify optimal timing."
},
{
"question": "How long should you cycle off peptides before restarting?",
"answer": "Growth hormone secretagogues: 4–8 weeks off after 8–12 weeks on to restore pituitary sensitivity. BPC-157 and thymosin beta-4: no mandatory off-cycle for injury recovery, but extended use beyond 12 weeks without breaks may reduce efficacy. Epithalon: minimum 2–3 months off between 10–20 day cycles. Thymalin: 2–3 months off after each 10-day cycle. Receptor downregulation is the primary reason for cycling. Continuous exposure reduces biological response over time."
},
{
"question": "What blood markers should you monitor during a peptide protocol?",
"answer": "IGF-1 (to track growth hormone axis response), fasting glucose and HbA1c (to monitor insulin sensitivity), liver enzymes (ALT, AST), complete blood count (for immune peptides like thymalin), and thyroid panel (TSH, Free T3, Free T4). Baseline testing 2–4 weeks before starting, then retest 6–8 weeks into the protocol. If IGF-1 rises above 300ng/mL or fasting glucose increases, consider dose reduction or cycle discontinuation."
}
]
}